The US Food and Drug Administration will likely bring any promising biomarkers for allergy and asthma treatments to an advisory committee review before endorsing their use for regulatory purposes.
“If things have real impact, they would probably go before an advisory committee at some point,” Ronald Rabin, chief of the laboratory of immunobiochemistry in the Center for Biologics Evaluation and Research’s Office of Vaccines Research and Review, said at the conclusion of a recent all-day workshop on the development and use of biomarkers in the regulation of